Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Gilead Sciences, Inc. GILD

• Dividend Yield: 4.47%
• Baird analyst Brian Skorney maintained a Neutral rating with a price target of $80 on June 20. This analyst has an accuracy rate of 64%.
• RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating with a price target of $74 on June 14. This analyst has an accuracy rate of 66%.
• Recent News: On June 26, Gilead Sciences Canada announced Phase 3 PURPOSE 1 Trial results.
• Benzinga Pro's real-time newsfeed alerted to latest GILD's news

CVS Health Corporation CVS

• Dividend Yield: 4.56%
• JP Morgan analyst Lisa Gill maintained an Overweight rating and cut the price target from $101 to $86 on May 30. This analyst has an accuracy rate of 60%.
• Argus Research analyst Chris Graja maintained a Buy rating and slashed the price target from $100 to $80 on May 8. This analyst has an accuracy rate of 69%.
• Recent News: On May 1, CVS Health reported first-quarter sales of $88.4 billion, up 3.7% year over year. It missed the consensus of $89.21 billion.
• Benzinga Pro's charting tool helped identify the trend in CVS stock.

Johnson & Johnson JNJ

• Dividend Yield: 3.40%
• Cantor Fitzgerald analyst LouiseChenreiterated an Overweight rating with a price target of $215 on June 25. This analyst has an accuracy rate of 69%.
• B of A Securities analyst GeoffMeachammaintained a Neutral rating and cut the price target from $180 to $170 on April 17. This analyst has an accuracy rate of 62%.
• Recent News: On June 21, Johnson & Johnson announced that it has successfully completed the acquisition of Proteologix, Inc.
• Benzinga Pro's signals feature notified of a potential breakout in JNJ’s shares.

Read More: How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro